Our findings are in line with the evidence from a recent meta-analysis conducted by Tager et al., who demonstrated an inverse relationship between the benefits on cardiovascular outcomes and SGLT2 selectivity in patients with HF [10]. The gene discussed is SLC5A2; the disease is hydrops fetalis.